title: Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.
abstract: Cytokine gene transfer to tumor cells has been demonstrated to induce tumor rejection in different murine models. However, controversial results were presented for different cytokines. In order to study the antitumorigenic activity that has been proposed for IL-6, the poorly immunogenic melanoma B16 and the colon adenocarcinoma CT26-murine cell lines, were transduced with recombinant retrovirus expressing rat IL-6. In vivo studies showed that IL-6-producing-B 16 cells inoculated s.c. in syngeneic mice, exhibited reduced tumorigenicity compared to vector-transduced B 16 cells. The histology of growing IL-6-producing tumors showed a "pseudo-nodular" pattern which correlated with a strong inhibition of the in vitro invasive capacity of these cells. IL-6-producing-B 16 cells did not develop tumors in athymic nude mice suggesting that the antitumor effect is not mediated by a normal host-T- and B-cell response. In contrast, IL-6-producing CT26 cells grew as tumors in syngeneic mice with a faster growth rate than parental and vector-transduced cells, in accordance with an increased in vitro growth kinetics. These results indicate that IL-6 expression by tumor cells demonstrate different effects depending on the tumor cell model.
authors.affiliation: Instituto de Investigaciones Bioquímicas Luis F. Leloir, Fundación Campomar, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina.
authors.forename: M F
authors.initials: MF
authors.lastname: Ledda
authors.forename: S
authors.initials: S
authors.lastname: Adris
authors.forename: A I
authors.initials: AI
authors.lastname: Bravo
authors.forename: L
authors.initials: L
authors.lastname: Bover
authors.forename: C
authors.initials: C
authors.lastname: Carbone
authors.forename: E
authors.initials: E
authors.lastname: Paleolog
authors.forename: J
authors.initials: J
authors.lastname: Mordoh
authors.forename: Y
authors.initials: Y
authors.lastname: Chernajovsky
authors.forename: O L
authors.initials: OL
authors.lastname: Podhajcer
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000276:immunology / Q000473:pathology; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D002455:Cell Division; D003110:Colonic Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology; D004195:Disease Models, Animal; D015870:Gene Expression; D005818:Genetic Engineering; D015850:Interleukin-6 / Q000235:genetics*; D007700:Kinetics; D008546:Melanoma, Experimental / Q000235:genetics / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000276:immunology / Q000473:pathology; D009368:Neoplasm Transplantation; D051381:Rats; D013601:T-Lymphocytes / Q000276:immunology; D014161:Transduction, Genetic; D014185:Transplantation, Isogeneic; D014407:Tumor Cells, Cultured / Q000276:immunology* / Q000473:pathology
chemical_list: D015850:Interleukin-6